• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Past Event

How Should the World Pay for a COVID-19 Vaccine?

Prof. Adrian Towse discusses the options for funding the development and manufacture of a vaccine, reflecting on their strengths and weaknesses, considering what may happen with no regional or global collaboration. Analysis will consider the work of Gavi and others…

Date

26/05/20 12:00 am

Prof. Adrian Towse discusses the options for funding the development and manufacture of a vaccine, reflecting on their strengths and weaknesses, considering what may happen with no regional or global collaboration. Analysis will consider the work of Gavi and others to construct a global vaccine market that delivers for all citizens.

Development and administration of a safe and effective vaccine, offering population-wide protection, is the ultimate solution to ridding the world of the scourge of COVID-19, saving lives, and allowing people to pick up their livelihoods and way of life.

The hunt for a vaccine is on with the Coalition for Epidemic Preparedness Innovations (CEPI) funding projects around the world; a number of academic groups, including a team in Oxford (UK), working on promising candidates; and vaccine candidates being pursued by major pharmaceutical companies through open science, collaborative and non-profit routes. J&J, for example, has committed to ‘bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use’ and Sanofi and GSK have announced their intention to collaborate on developing a vaccine candidate.

Yet there are commercial and scientific challenges, as set out in a Center for Global Development Note that Adrian Towse co-authored:

  • The development timeline required to establish safety and efficacy in vast numbers of otherwise healthy individuals (at least 12-18 months) creates a large market risk for potential developers (would people want to buy it?) on top of substantial scientific risk (would the product work?).
  • By the time a vaccine comes to market, will we need it anymore? SARS and MERS died out naturally. The 2014/2015 West African Ebola outbreak was fully controlled. Enough people may contract COVID-19 and recover to establish herd immunity. What if we repurpose and develop enough affordable and effective therapeutic options to manage the threat?
  • What if someone else comes to market with a better vaccine and a company’s up-front investment was for nothing?

We have seen moves in a number of countries to restrict patent rights for COVID vaccines and therapies; but perceived Intellectual Property (IP) risk will inevitably deter private sector investment even when companies are willing to work for returns that recognise the nature of the crisis. The search for a vaccine may be a long haul, requiring very substantial investments, despite our hope that it is not.

Several options have been put forward as to how a COVID-19 vaccine should be paid for, as an alternative to the competitive processes that drive most vaccine development and procurement. In particular:

  • That patents should be ‘bought out’ either for a price or ‘prize’ that reflects its value (or some share of it), or on a cost reimbursement basis.
  • There should be an advance commitment to purchase, again either at a price that reflects value or on a cost-plus basis.
  • Public or donor funding should be used to develop the vaccine with private sector actors surrendering rights in exchange for that public financial support.
  • Public and private vaccine developers should compete but expect to supply on a “not-for-profit” basis.

Into the mix, we must also factor manufacturing. Bill Gates has talked about the need to build capacity ‘at risk’ in advance of knowing if a vaccine in clinical development works, and his willingness for the Gates Foundation to fund this. For any vaccine to be successful, it needs to be available in middle- and low-income countries as well as in high income countries. If so, the capacity required will be on a scale never seen before. Countries do not currently vaccinate entire populations at the same time. To date, we have seen very limited international collaboration in this 2020 global health crisis, with many countries looking inwards, in contrast to the 2008 global financial crisis, when we saw innovative global action running in parallel to extraordinary national measures.

In this lecture, Adrian sets out the options for funding the development and manufacture of vaccines and their strengths and weaknesses, including what is likely to happen if there is no regional or global collaboration on the way forward. He will put this in the context of the work of The Vaccine Alliance (Gavi) and others to build a sustainable vaccine market that can deliver for populations of the world over time. Ideally, we will emerge from this pandemic not only with a successful COVID-19 vaccine, but with a better understanding of which policies work and which do not – knowledge which can produce lasting benefit in other areas of health need.

Related Research:

Silverman R, Krubiner C, Chalkidou K, Towse A. (2020) Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine. CGD Note. Center for Global Development. Available at https://www.cgdev.org/sites/default/files/Silverman-Krubiner-Chalkidou-Towse-R%26D-COVID.pdf

  • COVID-19 Research
  • Economics of Innovation
  • Annual Lecture

Related Events

Annual Lecture 2021
  • Past Event
  • Annual Lecture
  • September 2021

Virtual OHE Annual Lecture 2021: Do Patents Work? Evidence from Pharmaceutical Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!